Switch to:
Also traded in: Austria, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.63
WBA's Cash-to-Debt is ranked higher than
55% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.54 vs. WBA: 0.63 )
Ranked among companies with meaningful Cash-to-Debt only.
WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.43 Max: No Debt
Current: 0.63
Equity-to-Asset 0.42
WBA's Equity-to-Asset is ranked higher than
51% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. WBA: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.55 Max: 0.64
Current: 0.42
0.41
0.64
Interest Coverage 8.44
WBA's Interest Coverage is ranked lower than
68% of the 333 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.28 vs. WBA: 8.44 )
Ranked among companies with meaningful Interest Coverage only.
WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.72  Med: 39.24 Max: No Debt
Current: 8.44
Piotroski F-Score: 7
Altman Z-Score: 3.78
Beneish M-Score: -2.95
WACC vs ROIC
6.57%
11.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 4.82
WBA's Operating Margin % is ranked higher than
70% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. WBA: 4.82 )
Ranked among companies with meaningful Operating Margin % only.
WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.51  Med: 5.31 Max: 6.05
Current: 4.82
4.51
6.05
Net Margin % 3.66
WBA's Net Margin % is ranked higher than
74% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. WBA: 3.66 )
Ranked among companies with meaningful Net Margin % only.
WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.55 Max: 4.08
Current: 3.66
2.53
4.08
ROE % 14.19
WBA's ROE % is ranked higher than
73% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.73 vs. WBA: 14.19 )
Ranked among companies with meaningful ROE % only.
WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.63 Max: 19.24
Current: 14.19
9.67
19.24
ROA % 6.05
WBA's ROA % is ranked higher than
71% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.38 vs. WBA: 6.05 )
Ranked among companies with meaningful ROA % only.
WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 8.05 Max: 11.2
Current: 6.05
5.31
11.2
ROC (Joel Greenblatt) % 38.03
WBA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.29 vs. WBA: 38.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 29.67 Max: 39.26
Current: 38.03
24.31
39.26
3-Year Revenue Growth Rate 12.50
WBA's 3-Year Revenue Growth Rate is ranked higher than
80% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. WBA: 12.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 12.5 Max: 16.5
Current: 12.5
0.5
16.5
3-Year EBITDA Growth Rate 7.90
WBA's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 300 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. WBA: 7.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 12.3 Max: 18.3
Current: 7.9
-1.1
18.3
3-Year EPS without NRI Growth Rate 12.70
WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 267 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.50 vs. WBA: 12.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 14.1 Max: 20
Current: 12.7
-12.1
20
GuruFocus has detected 5 Warning Signs with Walgreens Boots Alliance Inc $WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WBA's 30-Y Financials

Financials (Next Earnings Date: 2017-06-29)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:OTCPK:RADLY, NYSE:RAD, OTCPK:MSMKF, OTCPK:JCOUF, OTCPK:CLCGY, NAS:PETS, OTCPK:ORIOY, NYSE:GNC, OTCPK:PRCXF, OTCPK:COCP, OTCPK:IWKCF, NAS:CJJD, OTCPK:OMHE, OTCPK:HEWA, OTCPK:SGIPF » details
Traded in other countries:WBA.Austria, W8A.Germany, WBA.Switzerland, 0R0C.UK,
Headquarter Location:USA
Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.

Walgreens is one of the nation's largest retail pharmacies, with about 8,175 drugstores throughout the United States. This large network of stores allows the firm the ability to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items. The firm also operates in-store health clinics.

Top Ranked Articles about Walgreens Boots Alliance Inc

Options Trades: covered-call reports for Cisco Systems, Facebook, Procter & Gamble, Walgreens Boots Alliance and Walmart Stores Inc.
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, Best Buy Inc., Marathon Oil Corporation and Walgreens Boots Alliance
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Comic Relief to Ring The Nasdaq Stock Market Closing Bell in Celebration of Red Nose Day
General Mills, Hi-Crush Partners LP, JP Morgan Chase, PayPal Holdings Inc., and Walgreens Boots Alliance and more offer option-trading opportunities that offer returns of more than 21%
Covered Call reports for Apple, Bank of America, Cardinal Health, CVS Health Corp., and Walgreens Boots Alliance include trade ideas that offer returns of 23% or more!
Francis Chou Adds to Valeant, Trims Sears in 4th Quarter Successful guru reports quarterly portfolio
Francis Chou (Trades, Portfolio), founder of Chou Associates Management, started an investment club in 1981 with six of his fellow telephone repairman. Throughout the next five years, Chou worked as a retail analyst at GW Asset Management where he met “Canadian Warren Buffett (Trades, Portfolio)” Prem Watsa (Trades, Portfolio). The successful guru established his flagship fund, the Chou Associate Fund, in 1986. On an annual basis, Chou’s fund outperformed the Standard & Poor’s 500 index benchmark by approximately 7% on Read more...
Insider Buys Highlight for Week of Feb. 6 Insiders bought shares of Walgreens Boots Alliance and Qualcomm
Walgreens Boots Alliance Inc. (NASDAQ:WBA): Co-COO Ornella Barra bought 124,000 shares Read more...
Insider Trades Roundup: Arconic, Walgreens, Alphabet Reviewing the largest insider buys and sales of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$2,000,000+,” the duration to “February 2017” and All Insider Sales to “$5,000,000+.” Read more...
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Deal’s value reduced by at least $2 billion
Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid Corp. (NYSE:RAD) announced on Monday they are reducing the price and postponing the close of their definitive merger agreement. Read more...
Weekly CEO Buys Insiders invest in Walgreens, American Assets, Heathcare Realty, General Electric, Triumph
According to GuruFocus’ Insider Data, these were the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
PE Ratio 19.88
WBA's PE Ratio is ranked higher than
54% of the 307 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.63 vs. WBA: 19.88 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 19.21 Max: 35.8
Current: 19.88
10.2
35.8
Forward PE Ratio 14.10
WBA's Forward PE Ratio is ranked higher than
75% of the 67 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.76 vs. WBA: 14.10 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.88
WBA's PE Ratio without NRI is ranked higher than
55% of the 304 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.85 vs. WBA: 19.88 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 19.21 Max: 35.8
Current: 19.88
10.2
35.8
Price-to-Owner-Earnings 12.00
WBA's Price-to-Owner-Earnings is ranked higher than
72% of the 206 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.94 vs. WBA: 12.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WBA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.76  Med: 15.89 Max: 40.18
Current: 12
8.76
40.18
PB Ratio 2.79
WBA's PB Ratio is ranked lower than
65% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.82 vs. WBA: 2.79 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.77 Max: 5.07
Current: 2.79
1.6
5.07
PS Ratio 0.73
WBA's PS Ratio is ranked lower than
64% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. WBA: 0.73 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.65 Max: 1.09
Current: 0.73
0.36
1.09
Price-to-Free-Cash-Flow 12.33
WBA's Price-to-Free-Cash-Flow is ranked higher than
68% of the 146 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.08 vs. WBA: 12.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.87  Med: 17.38 Max: 103.55
Current: 12.33
9.87
103.55
Price-to-Operating-Cash-Flow 10.36
WBA's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 191 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.30 vs. WBA: 10.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.43  Med: 11.47 Max: 21.27
Current: 10.36
6.43
21.27
EV-to-EBIT 16.30
WBA's EV-to-EBIT is ranked lower than
51% of the 320 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.88 vs. WBA: 16.30 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 12.8 Max: 25.1
Current: 16.3
6.3
25.1
EV-to-EBITDA 12.46
WBA's EV-to-EBITDA is ranked lower than
52% of the 329 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.83 vs. WBA: 12.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 10.05 Max: 18.8
Current: 12.46
4.9
18.8
PEG Ratio 4.98
WBA's PEG Ratio is ranked lower than
74% of the 180 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.06 vs. WBA: 4.98 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.63 Max: 8.78
Current: 4.98
0.5
8.78
Shiller PE Ratio 26.72
WBA's Shiller PE Ratio is ranked lower than
62% of the 87 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.36 vs. WBA: 26.72 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.95  Med: 24.72 Max: 45.86
Current: 26.72
13.95
45.86
Current Ratio 1.56
WBA's Current Ratio is ranked higher than
67% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. WBA: 1.56 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.66 Max: 2.36
Current: 1.56
1.19
2.36
Quick Ratio 1.03
WBA's Quick Ratio is ranked higher than
69% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.76 vs. WBA: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 1.7
Current: 1.03
0.27
1.7
Days Inventory 38.76
WBA's Days Inventory is ranked higher than
52% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.94 vs. WBA: 38.76 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 53.52 Max: 60.84
Current: 38.76
35.11
60.84
Days Sales Outstanding 17.84
WBA's Days Sales Outstanding is ranked lower than
56% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.07 vs. WBA: 17.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.78 Max: 24.17
Current: 17.84
11.04
24.17
Days Payable 47.27
WBA's Days Payable is ranked higher than
54% of the 276 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 43.87 vs. WBA: 47.27 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 48.01
Current: 47.27
28.73
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.93
WBA's Dividend Yield % is ranked higher than
54% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.94 vs. WBA: 1.93 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.54  Med: 1.72 Max: 3.11
Current: 1.93
0.54
3.11
Dividend Payout Ratio 0.38
WBA's Dividend Payout Ratio is ranked higher than
57% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. WBA: 0.38 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.31 Max: 0.64
Current: 0.38
0.16
0.64
3-Year Dividend Growth Rate 8.50
WBA's 3-Year Dividend Growth Rate is ranked higher than
54% of the 185 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. WBA: 8.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 13.7 Max: 26
Current: 8.5
3.8
26
Forward Dividend Yield % 1.93
WBA's Forward Dividend Yield % is ranked lower than
55% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. WBA: 1.93 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.66
WBA's 5-Year Yield-on-Cost % is ranked higher than
63% of the 506 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.06 vs. WBA: 3.66 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.03  Med: 3.28 Max: 5.94
Current: 3.66
1.03
5.94
3-Year Average Share Buyback Ratio -4.60
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.70 vs. WBA: -4.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5  Med: 0 Max: 3.5
Current: -4.6
-5
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.11
WBA's Price-to-Tangible-Book is ranked lower than
96% of the 322 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.07 vs. WBA: 16.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.94  Med: 3.96 Max: 58.76
Current: 16.11
1.94
58.76
Price-to-Intrinsic-Value-Projected-FCF 1.25
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 230 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.49 vs. WBA: 1.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 2.61 Max: 18.64
Current: 1.25
0.73
18.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.67
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
60% of the 53 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.43 vs. WBA: 1.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.12
WBA's Price-to-Median-PS-Value is ranked higher than
51% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. WBA: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.11 Max: 3.19
Current: 1.12
0.56
3.19
Price-to-Peter-Lynch-Fair-Value 3.50
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
81% of the 103 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.66 vs. WBA: 3.50 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.93 Max: 6.3
Current: 3.5
0.57
6.3
Price-to-Graham-Number 3.77
WBA's Price-to-Graham-Number is ranked lower than
88% of the 267 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.51 vs. WBA: 3.77 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WBA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 2.01 Max: 8.07
Current: 3.77
0.99
8.07
Earnings Yield (Greenblatt) % 6.13
WBA's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.55 vs. WBA: 6.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 7.8 Max: 15.9
Current: 6.13
4
15.9
Forward Rate of Return (Yacktman) % 10.99
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 246 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.97 vs. WBA: 10.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7  Med: 14.5 Max: 23.7
Current: 10.99
7
23.7

More Statistics

Revenue (TTM) (Mil) $116,081.00
EPS (TTM) $ 3.90
Beta0.86
Short Percentage of Float1.17%
52-Week Range $75.18 - 88.00
Shares Outstanding (Mil)1,080.95

Analyst Estimate

Aug17 Aug18 Aug19
Revenue (Mil $) 117,753 123,937 136,785
EPS ($) 4.97 5.32 6.08
EPS without NRI ($) 4.97 5.32 6.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.57%
Dividends per Share ($) 1.49 1.55 1.71
» More Articles for WBA

Headlines

Articles On GuruFocus.com
Options Trades: covered-call reports for Cisco Systems, Facebook, Procter & Gamble, Walgreens Boots Jun 19 2017 
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, B May 26 2017 
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Comic Relief to Ring The Nasdaq Stock Market Closin May 23 2017 
General Mills, Hi-Crush Partners LP, JP Morgan Chase, PayPal Holdings Inc., and Walgreens Boots Alli May 02 2017 
CVS Health Trading at Discount to Fair Value Apr 26 2017 
Covered Call reports for Apple, Bank of America, Cardinal Health, CVS Health Corp., and Walgreens Bo Apr 19 2017 
Walgreens Boots Alliance: Strong Outlook Regardless of Rite Aid Outcome Apr 13 2017 
Here Comes 'The Fed Is Meeting' Folly, Right on Schedule Mar 09 2017 
Francis Chou Adds to Valeant, Trims Sears in 4th Quarter Feb 16 2017 
ANGEL Program Gets National Attention Feb 13 2017 

More From Other Websites
Treasury Bonds Continue Their Worrying Rally Jun 27 2017
Rite Aid Stock Explodes 30% Higher on Report of FTC Approval for Walgreen's Acquisition Jun 26 2017
Why Fred's, Inc. and Rite Aid Corporation Stock Popped Today Jun 26 2017
This Is Why Rite Aid Stock Skyrocketed 30% Jun 26 2017
Buy Rite Aid Corporation (RAD) Stock Before FTC Approves Its Merger Jun 26 2017
Drugstore stocks are surging right now Jun 26 2017
Wall Street Sees a 22% Upside in Walgreens Jun 26 2017
Comparing Walgreens’s Stock Market Performance with Its Peers’ Jun 26 2017
After 20 Months, Still No Walgreens–Rite Aid Deal Approval Jun 26 2017
Why Rite Aid Corporation (RAD) Stock Hasn’t Lost an Ounce of Risk Jun 25 2017
[$$] EU/Mexico trade talks, German data, Monsanto and Walgreens report Jun 25 2017
Rite Aid Stock Has a Lot to Prove on Thursday Jun 24 2017
Where Will Walgreens’ Earnings Head in Fiscal 3Q17? Jun 23 2017
Movement at the FTC Is Bad News for Rite Aid Jun 23 2017
Discussing Walgreens’s Top Line ahead of Its Fiscal 3Q17 Results Jun 23 2017
Will Walgreens Continue Its Hit-and-Miss Saga in Fiscal 3Q17? Jun 23 2017
Walgreens Boots Alliance Inc (WBA) Stock Won’t Yield to Amazon Jun 23 2017
'Walmart Rx' Takes Center Stage as Walgreens Rite Aid Saga Nears Long Overdue End Jun 23 2017
Why Rite Aid Corporation (RAD), Dr Pepper Snapple Group Inc. (DPS) and Accenture Plc (ACN) Are 3 of... Jun 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}